Esophageal Cancer Articles & Analysis
28 news found
Sutro has two wholly owned ADCs in the clinic—STRO-002, a folate receptor alpha (FolRα)-targeting ADC, in clinical studies for ovarian and endometrial cancers; and STRO-001, a CD74-targeting ADC, in clinical studies for B-cell malignancies. Additionally, Sutro is collaborating with Bristol Myers Squibb (BMS) on CC-99712, a BCMA-targeting ADC in the clinic for patients ...
Meshinchi is Professor, Clinical Research Division, at Fred Hutchinson Cancer Research Center and Professor, Division of Pediatric Hematology-Oncology, at the University of Washington School of Medicine. ...
Sutro has two wholly owned ADCs in the clinic—STRO-002, a folate receptor alpha (FolRα)-targeting ADC, in clinical studies for ovarian and endometrial cancers; and STRO-001, a CD74-targeting ADC, in clinical studies for B-cell malignancies. Additionally, Sutro is collaborating with Bristol Myers Squibb (BMS) on CC-99712, a BCMA-targeting ADC in the clinic for patients ...
Sutro has two wholly owned ADCs in the clinic—STRO-002, a folate receptor alpha (FolRα)-targeting ADC, in clinical studies for ovarian and endometrial cancers; and STRO-001, a CD74-targeting ADC, in clinical studies for B-cell malignancies. Additionally, Sutro is collaborating with Bristol Myers Squibb (BMS) on CC-99712, a BCMA-targeting ADC in the clinic for patients ...
WATS3D uses a unique wide-area sampling instrument, proprietary 3D imaging with AI analysis, and expert pathologists to reliably identify abnormal cells to help physicians prevent esophageal cancer. “The CPU is based on a thorough review of the existing clinical literature and expert opinion. ...
Sutro has two wholly owned ADCs in the clinic—STRO-002, a folate receptor alpha (FolRα)-targeting ADC, in clinical studies for ovarian and endometrial cancers; and STRO-001, a CD74-targeting ADC, in clinical studies for B-cell malignancies. Additionally, Sutro is collaborating with Bristol Myers Squibb (BMS) on CC-99712, a BCMA-targeting ADC in the clinic for patients ...
We are excited about the potential this therapeutic may have for cancer patients.” Under the terms of the July 2018 collaboration agreement between Sutro and Merck, Sutro has been primarily responsible for preclinical research and development, as well as manufacturing, of cytokine derivatives utilizing Sutro’s proprietary cell-free protein synthesis and ...
Short for wide-area transepithelial sampling with three-dimensional analysis, WATS3D utilizes enhanced tissue acquisition, 3D imaging with AI-powered analysis, and expert pathologists to reliably detect Barrett’s esophagus (BE) and esophageal dysplasia. Effective immediately, the agreement makes WATS3D available to the 565,000 members of BCBS of South Carolina with all ...
In patients with head and neck cancer, radiotherapy is a mainstay of treatment. Approximately 70 percent of patients receiving radiotherapy for head and neck cancer develop SOM, defined by the inability to eat solid food or drink liquids. ...
WATS3D, an AI powered diagnostic platform developed by CDx Diagnostics to empower physicians to reliably detect Barrett’s esophagus (BE) and esophageal dysplasia to help prevent esophageal cancer, was designated as medically necessary by Highmark, Inc. health plans in Delaware, Pennsylvania, and West Virginia in Q4 2021. ...
(OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence a clinical trial of the Biostage Esophageal Implant, or BEI, for severe esophageal ...
In patients with head and neck cancer, radiotherapy is a mainstay of treatment. Approximately 70 percent of patients receiving radiotherapy for head and neck cancer develop SOM, defined by the inability to eat solid food or drink liquids. ...
(OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence a clinical trial of the Biostage Esophageal Implant for severe esophageal disease including ...
” Highlights from the first quarter and recent weeks include: The American College of Gastroenterology (“ACG”) updated its clinical guideline for the diagnosis and management of esophageal precancer, endorsing, for the first time, nonendoscopic biomarker screening to detect precancer and prevent highly lethal esophageal ...
(Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. ...
” About EsoGuard® and EsoCheck® Millions of patients with GERD are at risk of developing esophageal precancer and a highly lethal form of esophageal cancer (“EAC”). ...
No Grade 4 or 5 esophagitis in patients treated with avasopasem Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced topline results from the six-week, Phase 2a, ...
(OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence a clinical trial of the Biostage Esophageal Implant for severe esophageal disease including ...
(OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence a clinical trial of the Biostage Esophageal Implant for severe esophageal disease ...
A newly published study as lead article in Gastrointestinal Endoscopy shows that Barrett’s esophagus (BE) and dysplasia progress to esophageal cancer at similar, or even higher, rates when diagnosed by WATS3D (wide-area transepithelial sampling with three-dimensional analysis) as they do when diagnosed by conventional forceps biopsies. ...